Date: 01-11-2023

Your Name: Tine Oestergaard

Manuscript Title: Autoimmune and Neoplastic Comorbidities in Patients from the National Danish TET Database

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 6 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | XNone | |
|----|---|--------|--|
| 7 | Support for attending meetings and/or travel | XNone | |
| 8 | Patents planned, issued or pending | XNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | |
| 11 | Stock or stock options | XNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X_None | |
| 13 | Other financial or non- financial interests | XNone | |
| | | | |

Please summarize the above conflict of interest in the following box:

| None. | | |
|-------|--|--|
| | | |

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 1/11-2023

Your Name: Caroline Bjerke

Manuscript Title: Autoimmune and Neoplastic Comorbidities in Patients from the National Danish TET

Database

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | | 30 months |
| | any entity (if not indicated in item #1 above). | _xNone | |
| 3 | Royalties or licenses | x_None | |
| 4 | Consulting fees | _xNone | |

| 5 | Payment or honoraria for | xNone | |
|------|---|--------------------------------|------------|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | xNone | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | xNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | xNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | xNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | xNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | x_None | |
| | | | |
| 42 | | | |
| 12 | Receipt of equipment, | xNone | |
| | materials, drugs, medical writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | x None | |
| 13 | financial interests | | |
| | ariolar irrect ests | | |
| Plea | se summarize the above co | nflict of interest in the foll | owing box: |
| | | | |

Please place an "X" next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 01-11-2023

Your Name: Thomas Hartvig Lindkær Jensen

Manuscript Title: Autoimmune and Neoplastic Comorbidities in Patients from the National Danish TET Database

Manuscript number (if known):_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| 3 | Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses | Time frame: pastXNoneXNone | 36 months |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | |
|------|--|---------------------------------------|-------------|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| _ | educational events | | |
| 6 | Payment for expert | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| , | Support for attending meetings and/or travel | None | |
| | meetings and/or traver | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | X None | |
| O | pending | | |
| | k-2 | | |
| 0 | Daubiainabian arr - D-t- | V Nege | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| 10 | in other board, society, | XNone | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | X None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | X_None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | XNone | |
| | financial interests | | |
| | | | |
| | | | |
| DI - | | aditar ad tarras services to the con- | austra kann |
| Plea | se summarize the above co | nflict of interest in the foll | owing box: |
| N. | None. | | |
| " | one. | | |
| | | | |
| | | | |

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 01.11.2023

Your Name: Katharina A. Perell

Manuscript Title: Autoimmune and Neoplastic Comorbidities in Patients from the National Danish TET Database

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | x_None | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses | Time frame: pastxNonexNone | 36 months |
| 4 | Consulting fees | xNone | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | x_None | | |
|------|--|---------------------------|------------------------|--|
| 6 | Payment for expert | xNone | | |
| | testimony | | | |
| 7 | Support for attending meetings and/or travel | xNone | | |
| | | | | |
| 8 | Patents planned, issued or | xNone | | |
| | pending | | | |
| 9 | Participation on a Data | xNone | | |
| | Safety Monitoring Board or | | | |
| 10 | Advisory Board Leadership or fiduciary role | x None | | |
| 10 | in other board, society, | xNone | | |
| | committee or advocacy | | | |
| 11 | group, paid or unpaid Stock or stock options | x None | | |
| | Stock of Stock options | | | |
| 40 | | | | |
| 12 | Receipt of equipment, materials, drugs, medical | xNone | | |
| | writing, gifts or other | | | |
| 42 | services | N | | |
| 13 | Other financial or non- financial interests | xNone | | |
| | | | | |
| Plea | Please summarize the above conflict of interest in the following box: | | | |
| Plea | se place an "X" next to the | following statement to in | dicate your agreement: | |

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| Date: | May 19. 2023 | | | |
|-------------------------------|---|--|--|--|
| Your Name: | Rene Horsleben Petersen | | | |
| Manuscript Tit | le: Autoimmune and Neoplastic Comorbidities in Patients from the National Danish TET Database | | | |
| Manuscript number (if known): | | | | |
| | | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _xNone | |
| 3 | Royalties or licenses | xNone | |
| 4 | Consulting fees | x_None | |

| 5 | Payment or honoraria for | None | Speaker fee: Medtronic, AMBU, AstraZeneca, Medela | | |
|------|---|--------|---|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| | educational events | | | | |
| 6 | Payment for expert | _xNone | | | |
| | testimony | | | | |
| | | | | | |
| 7 | Support for attending meetings and/or travel | _xNone | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | x_None | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data Safety Monitoring Board or | None | Advisory Board: AstraZeneca, BMS, Roche, MSD | | |
| | | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | _xNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy group, paid or unpaid | | | | |
| 11 | Stock or stock options | _xNone | | | |
| | | | | | |
| | | | | | |
| 12 | Receipt of equipment, | x_None | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other | | | | |
| | services | | | | |
| 13 | Other financial or non- | x_None | | | |
| | financial interests | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| Plea | Please summarize the above conflict of interest in the following box: | | | | |

| Speaker fee: Medtronic, AMBU, AstraZeneca, Medela Advisory Board: AstraZeneca, BMS, Roche, MSD | | | | |
|---|--|--|--|--|
| | | | | |
| | | | | |
| | | | | |

Please place an "X" next to the following statement to indicate your agreement:

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: November 1, 2023

Your Name: Peter Meidahl Petersen

Manuscript Title: Autoimmune and Neoplastic Comorbidities in Patients from the National Danish TET Database

Manuscript number (if known):_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | | | | | |
|---|--|--|---|--|--|--|--|--|
| | Time frame: Since the initial planning of the work | | | | | | | |
| 1 | manuscript (e.g., funding, | XNone | | | | | | |
| | provision of study materials, | | | | | | | |
| | medical writing, article processing charges, etc.) | | | | | | | |
| | No time limit for this item. | | | | | | | |
| | No time initial for this item. | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | Time frame: past | 36 months | | | | | |
| 2 | Grants or contracts from | XNone | | | | | | |
| | any entity (if not indicated | | | | | | | |
| | in item #1 above). | | | | | | | |
| 3 | Royalties or licenses | XNone | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| 4 | Consulting fees | XNone | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| 6 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | XNone | | | | |
|----|---|--------|--|--|--|--|
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| 8 | Patents planned, issued or pending | XNone | | | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | | | | |
| 11 | Stock or stock options | XNone | | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X_None | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | | | | | | |

Please summarize the above conflict of interest in the following box:

| None. | | |
|-------|--|--|
| | | |

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.